Physician profile
Michael Adling
NPI 1669811139
$1,679.18
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.17 · 2020: $85.92 · 2021: $68.93 · 2022: $493 · 2023: $595 · 2024: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $543.27 | 2022-2024 | Farxiga, Breztri |
| Abbvie INC. | $232.29 | 2020-2024 | Ubrelvy, Qulipta, Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $209.03 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $143.42 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $142.03 | 2019-2022 | |
| Amgen INC. | $121.23 | 2022 | |
| Boston Scientific Corporation | $88.08 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.85 | 2020 | |
| Merck Sharp & Dohme LLC | $47.27 | 2019-2021 | |
| Sanofi Pasteur INC. | $25.73 | 2023 | |
| Abbott Laboratories | $24.36 | 2021 | |
| Novo Nordisk INC | $18.12 | 2023 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $16.57 | 2021 | |
| Phadia US INC. | $14.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Adling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.